RxDoctor Payments Data

Anoop Goyal, MD

Gastroenterology · Palm Harbor, FLNPI 1164485751

Payments from drug & device makers

$160,673in general payments, 2019–2025

Across 16 payments — averaging $10,042 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$160K
  • AbbVie$354
  • Boston Scientific$139
  • Medtronic$138
  • Gilead$57
  • Cook Medical LLC$35
  • plus $16 from 1 others
$42,159in research payments, 2019–2025

Across 1 payment — averaging $42,159 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$42K

What the payments were for

  • Food & beverage$739100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$160,673 in reported general payments places this provider in the 90th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$240,527
Medicare patients
514
Services billed
2,045

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin29$91,036
LinzessLinaclotide43$29,947
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl164$2,673
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg55$1,244
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates16$1,115
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl36$706
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl40$651
Pantoprazole Sodium66$633
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine21$425
Sucralfate14$395
Spironolactone22$312
Famotidine37$296
Ondansetron Hcl11$173
Furosemide24$63

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$354$29,94743 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Palm Harbor

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →